18,250 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 18,250 shares of the biopharmaceutical company’s stock, valued at approximately $8,371,000.

Other hedge funds also recently bought and sold shares of the company. AlphaQuest LLC raised its holdings in shares of Madrigal Pharmaceuticals by 412.5% in the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 66 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter worth about $428,000. Bank of New York Mellon Corp increased its position in Madrigal Pharmaceuticals by 46.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 88,943 shares of the biopharmaceutical company’s stock worth $26,918,000 after purchasing an additional 28,154 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in Madrigal Pharmaceuticals by 98.3% in the 2nd quarter. Los Angeles Capital Management LLC now owns 5,149 shares of the biopharmaceutical company’s stock valued at $1,558,000 after purchasing an additional 2,553 shares during the last quarter. Finally, Allworth Financial LP lifted its holdings in Madrigal Pharmaceuticals by 17,570.0% in the 2nd quarter. Allworth Financial LP now owns 3,534 shares of the biopharmaceutical company’s stock valued at $1,070,000 after purchasing an additional 3,514 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Stock Performance

Madrigal Pharmaceuticals stock opened at $432.83 on Friday. The stock’s 50 day moving average price is $492.64 and its 200 day moving average price is $487.47. The firm has a market capitalization of $9.93 billion, a PE ratio of -33.63 and a beta of -0.97. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.77 and a current ratio of 4.01. Madrigal Pharmaceuticals, Inc. has a one year low of $265.00 and a one year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($2.61). The firm had revenue of $321.08 million during the quarter, compared to analyst estimates of $310.36 million. Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The firm’s revenue was up 210.8% compared to the same quarter last year. During the same period last year, the business earned ($2.71) EPS. As a group, sell-side analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Rebecca Taub sold 18,650 shares of Madrigal Pharmaceuticals stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $552.15, for a total transaction of $10,297,597.50. Following the sale, the director owned 461,044 shares of the company’s stock, valued at $254,565,444.60. The trade was a 3.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Mardi Dier sold 1,982 shares of the business’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $430.87, for a total transaction of $853,984.34. Following the completion of the transaction, the chief financial officer owned 12,490 shares in the company, valued at $5,381,566.30. This represents a 13.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 99,062 shares of company stock valued at $52,317,727. Corporate insiders own 21.50% of the company’s stock.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Zacks Research raised shares of Madrigal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. HC Wainwright boosted their price target on Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the company a “buy” rating in a report on Friday, November 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, January 22nd. Truist Financial boosted their target price on shares of Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Finally, Wolfe Research set a $579.00 price target on Madrigal Pharmaceuticals in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $685.31.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.